Youngil Koh

23PUBLICATIONS
126CO-AUTHORS
Molecular targetsMedical virologyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Aug 18, 2026
Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study.

|Aug 11, 2026
Real-World Treatment Patterns for Waldenstrom Macroglobulinemia: Implications for Treatment Sequencing.

|Jun 24, 2026
Nuanced treatment decision in newly diagnosed multiple myeloma patients aged 65-75 years: a real-world study.

|Jun 12, 2026
Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).

|Jan 15, 2026
Infections after bispecific antibodies in B-cell lymphomas.

Dong Hyun Kim, Naryllae Lee, Youngil Koh

|Dec 04, 2025
Clinical Outcomes of Low-Grade Cytomegalovirus DNAemia in Hematopoietic Stem Cell Transplantation Recipients Receiving Letermovir Prophylaxis.

Jung Soo Son, Eun-Jeong Jeong, Hyeon Jae Jo

Pageof 4

Frequent Collaborators

12 joint publications

Jamin Byun

12 joint publications

Sung-Soo Yoon

6 joint publications

Junshik Hong

6 joint publications

Dong-Yeop Shin